New asthma drug cuts severe attacks in Hard-to-Treat patients

NCT ID NCT05329194

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested a drug called tezepelumab in 287 adults and teens with severe asthma, including groups often left out of research. The goal was to see if the drug reduces asthma attacks and is safe over 52 weeks. Results showed fewer flare-ups compared to the year before starting the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Show contact details

Locations

Research Site

Mobile, Alabama, 36608, United States
Research Site

Gilbert, Arizona, 85234, United States
Research Site

Long Beach, California, 90815, United States
Research Site

Los Angeles, California, 90017, United States
Research Site

Rancho Mirage, California, 92270, United States
Research Site

Westminster, California, 92683, United States
Research Site

Colorado Springs, Colorado, 80907, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Washington D.C., District of Columbia, 20037, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Lexington, Kentucky, 40509, United States
Research Site

New Orleans, Louisiana, 70112, United States
Research Site

Upper Marlboro, Maryland, 20772, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Ypsilanti, Michigan, 48197, United States
Research Site

Saint Paul, Minnesota, 55109, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Lincoln, Nebraska, 68505, United States
Research Site

Omaha, Nebraska, 68114, United States
Research Site

Hollis, New York, 11423, United States
Research Site

Horseheads, New York, 14845, United States
Research Site

Rochester, New York, 14642, United States
Research Site

Valhalla, New York, 10595, United States
Research Site

Chapel Hill, North Carolina, 27514, United States
Research Site

Wilmington, North Carolina, 28401, United States
Research Site

Toledo, Ohio, 43617, United States
Research Site

Oklahoma City, Oklahoma, 73120, United States
Research Site

Altoona, Pennsylvania, 16602, United States
Research Site

Philadelphia, Pennsylvania, 19140, United States
Research Site

Warwick, Rhode Island, 02886, United States
Research Site

Greenville, South Carolina, 29607, United States
Research Site

Hendersonville, Tennessee, 37075, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

McKinney, Texas, 75069, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Charlottesville, Virginia, 22903, United States
Research Site

Vancouver, Washington, 98664, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.